Related Organizations
Related News
April 07, 2021
How does an idea that is too unconventional for mainstream channels get funded? Often, even venture capitalist firms are too risk-averse, and government funding agencies are too entrenched in the status quo, to consider the most revolutionary ideas. Commonly given advice in the start-up world tells us to first look to the three F's: family,...
October 05, 2020
More and more investors are starting to get interested in technologies that are being developed to slow or even reverse aging as therapies are starting to reach human trials. Recently, I attended the Longevity Investors Conference to learn more about investments being made towards anti-aging research. A shift towards doing something about aging The current...
May 18, 2020
Investment mogul Jim Mellon has donated a record-breaking 1 million British pounds to Oriel College in the United Kingdom, offering a ray of light for aging research. Supporting fundamental research on aging In recent years, one of the real dynamos of our community has been British investor and philanthropist Jim Mellon. Jim is perhaps best...
September 29, 2017
Jim Mellon and Al Chalabi are back with another successful venture into the world of science investment. Following their acclaimed 2012 book “Cracking the code”, whose spotlight was on the life sciences industry, Juvenescence takes us on a compelling journey through the dawning market of longevity and rejuvenation biotechnology, which the authors predict will be...
September 27, 2017
Only two years ago, when I launched my advocacy website Rejuvenaction, I didn’t think I would read a book like Juvenescence so soon; yet, the topic of rejuvenation biotechnologies has already become mainstream enough to lead investors of the calibre of Jim Mellon and Al Chalabi to devote a whole book to it. As Juvenescence...
September 18, 2017
Today, we are pleased to announce the imminent arrival of Jim Mellon and Al Chalabi's new book Juvenescence, which covers the field of rejuvenation biotechnology. The book focuses on technologies that will soon arrive, therapies that may increase healthy lifespan, and guidance for investors. The book offers a comprehensive overview of aging research and how...
